{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 43,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow diagram to illustrate dose escalation strategies (Accelerated vs Standard vs Priming).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/39",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Group A, B, and C titration flowcharts",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2295699-8c2b-4ddf-8045-996729f2a5b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.65,
        "y": 0.2
      },
      "kind": "list",
      "text": "Part 1: Up to 128 patients with advanced adenocarcinoma; Part 2: Open-label study to evaluate efficacy and safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22f4b978-781d-46a6-a261-9fccc1c8cc0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "DL1A: MABEL based starting dose 0.04 µg/kg; The actual number of dose levels (cohorts) in Accelerated Titration will depend on the dose level at which the first Grade ≥2 AE or DLT occurs; MTD: Maximum tolerated dose; PAD: Pharmacologically active dose; Dosing schedule: every week (QW) initially, every two weeks (Q2W) may also be explored; PDL1C: first priming dose level; PDLXC: final priming dose level",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06699e03-3498-45de-a126-9c87838758e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 1/2 trial design in advanced adenocarcinoma",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20853432-0712-46cd-bad1-c39a207c4813",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "FDA cleared IND for CAB-EpCAMxCAB-CD3 bispecific TCE (BA3182)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ef2f35d-6945-4ff7-ad03-9dca73b1997b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "93551341-596a-4991-aed4-396d28a6b03f",
      "evidence": "Flowchart of clinical trial dose escalation",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}